Several randomized trials tested the anti-VEGF monoclonal antibody, bevacizumab, in combination with standard chemotherapy in SCLC patients, showing poor results and no clear survival benefits [65,66]. This evidence concerns the gene VEGFA and small cell lung carcinoma.